Tue, May 13, 8:57 PM (39 days ago)
**Silexion Therapeutics Corp (SLXN) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** No revenue generated; the company is in the development stage. - **Net Loss:** $1.7 million (Q1 2025) vs. $1.4 million (Q1 2024), an increase of 21.4%. - **Operating Expenses:** $1.7 million (Q1 2025) vs. $1.3 million (Q1 2024). - **R&D Expenses:** $590,000 (Q1 2025) vs. $961,000 (Q1 2024), a decrease of 38.7%. - **General & Administrative Expenses:** $1,060,000 (Q1 2025) vs. $289,000 (Q1 2024), an increase of 266.7%. - **Cash Flow:** Net cash used in operating activities was $2.5 million (Q1 2025) vs. $1.8 million (Q1 2024). - **Cash Position:** $6.2 million in cash and cash equivalents as of March 31, 2025. **Profit Margins:** - Not applicable as the company has not generated revenue. **Earnings Changes:** - Net loss per share increased to $0.26 (Q1 2025) from $12.29 (Q1 2024) due to a 1-for-9 reverse share split. **Quarterly Performance Discussion:** - The increase in net loss was primarily due to higher general and administrative expenses related to public company operations. - R&D expenses decreased due to a shift in focus from API development to manufacturing. - The company raised $5.0 million from a public offering and $3.3 million from an induced warrant exercise transaction. **Trends & Uncertainties:** - The company expects to continue incurring significant expenses and operating losses. - Substantial additional funding will be required to finance operations, expand the business, and pipeline. - There is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the date of the financial statements. **Future Operations Impact:** - The company plans to apply for Orphan Drug Designation, conduct toxicological studies, initiate clinical trials, and seek marketing approvals for SIL204. - Additional product candidates may be added to the pipeline. - The company will need to raise additional capital to support these activities.